Validity of the 13C-Caffeine Breath Test as a Noninvasive, Quantitative Test of Liver Function

Hepatology

Volumn 38, Issue 5, 2003, Pages 1227-1236

  Park, Gordon Jung Hyuk ^a,b   Katelaris, Peter Harry ^a   Jones, D Brian ^a   Seow, Francis ^a   Le Couteur, David George ^a   Ngu, Meng Chong ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; CAFFEINE; CARBON; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CAFFEINE BREATH TEST; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SMOKING; BLOOD; CASE CONTROL STUDY; KINETICS; LIVER; LIVER DISEASE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; VALIDATION STUDY;

ADULT; AGED; BREATH TESTS; CAFFEINE; CARBON ISOTOPES; CASE-CONTROL STUDIES; FEMALE; HUMANS; KINETICS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REPRODUCIBILITY OF RESULTS; SMOKING;

EID: 0142213951     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50475     Document Type: Article

References (36)

1. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 1982;32:98-106.
2. Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 1983;24:93-98.
3. Arnaud MJ, Welsch C. Theophylline and caffeine metabolism in man. In: Rietbock N, Woodcock BG, Staib A, eds. Theophylline and other methylxanthines. Braunschweig/Wiesbaden: Vieweg and Son, 1981:135-148.
4. Desmond PV, Patwardhan RV, Johnson RF, Schenker S. Impaired elimination of caffeine in cirrhosis. Dig Dis Sci 1980;25:193-197.
5. Statland BE, Demas T, Danis M. Letter: caffeine accumulation associated with alcoholic liver disease. N Engl J Med 1976;295:110-111.
6. Shyu JK, Wang YJ, Lee SD, Lu RH, Lo KJ. Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. Zhonghua Yi Xue Za Zhi (Taipei) 1996;57:329-334.
7. Jover R, Carnicer F, Sanchez-Paya J, Climent E, Sirvent M, Marco JL. Salivary caffeine clearance predicts survival in patients with liver cirrhosis. Am J Gastroenterol 1997;92:1905-1908.
8. Jost G, Wahllander A, von Mandach U, Preisig R. Overnight salivary caffeine clearance: a liver function test suitable for routine use. HEPATOLOGY 1987;7:338-344.
9. Zysset T, Wahllander A, Preisig R. Evaluation of caffeine plasma levels by an automated enzyme immunoassay (EMIT) in comparison with a high-performance liquid chromatographic method. Ther Drug Monit 1984;6: 348-354.
10. Zylber-Katz E, Granit L, Levy M. Relationship between caffeine concentrations in plasma and saliva. Clin Pharmacol Ther 1984;36:133-137.
11. Wietholtz H, Voegelin M, Arnaud MJ, Bircher J, Preisig R. Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test. Eur J Clin Pharmacol 1981;21:53-59.
12. 2 breath test. Dev Pharmacol Ther 1989;12:90-95.
13. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992;52:170-180.
14. Parker AC, Preston T, Heaf D, Kitteringham NR, Choonara I. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol 1994;38:573-576.
15. Parker AC, Pritchard P, Preston T, Dalzell AM, Choonara I. Lack of inhibitory effect of cimetidine on caffeine metabolism in children using the caffeine breath test. Br J Clin Pharmacol 1997;43:467-470.
16. Renner E, Wietholtz H, Huguenin P, Arnaud MJ, Preisig R. Caffeine: a model compound for measuring liver function. HEPATOLOGY 1984;4:38-46.
17. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
18. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
19. 2 breath tests as monitors of the cytochrome P450 dependent mixed function monooxygenase system. Prog Clin Biol Res 1983;135:119-145.
20. Preston T, McMillan DC. Rapid sample throughput for biomedical stable isotope tracer studies. Biomed Environ Mass Spectrom 1988;16:229-235.
21. Craig H. Isotopic standards for carbon and oxygen and correction factors for mass-spectrometric analysis of carbon dioxide. Geochim Cosmochim Acta 1957;12:133-149.
22. Parsons WD, Neims AH. Effect of smoking on caffeine clearance. Clin Pharmacol Ther 1978;24:40-45.
23. Villeneuve JP, Infante-Rivard C, Ampelas M, Pomier-Layrargues G, Huet PM, Marleau D. Prognostic value of the aminopyrine breath test in cirrhotic patients. HEPATOLOGY 1986;6:928-931.
24. 14C-aminopyrine breath test compared to the Child-Pugh score and serum bile acids in 84 cirrhotic patients. Digestion 1991; 50:212-218.
25. Merkel C, Bolognesi M, Bellon S, Bianco S, Honisch B, Lampe H, Angeli P, et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992;33:836-842.
26. Urbain D, Muls V, Thys O, Ham HR. Aminopyrine breath test improves long-term prognostic evaluation in patients with alcoholic cirrhosis in Child classes A and B. J Hepatol 1995;22:179-183.
27. Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989;24:269-276.
28. Herold C, Ganslmayer M, Ocker M, Zopf S, Gailer B, Hahn EG, Schuppan D. Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol 2003;18:445-449.
29. Lambert GH, Schoeller DA, Kotake AN, Flores C, Hay D. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther 1986;9:375-388.
30. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase ratios. Clin Pharmacol Ther 1991;50:508-519.
31. Horn EP, Tucker MA, Lambert G, Silverman D, Zametkin D, Sinha R, Hartge T, et al. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev 1995;4:529-533.
32. 2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982;32:261-269.
33. George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. HEPATOLOGY 1995;21:120-128.
34. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 1989;86:7696-7700.
35. 13C-urea breath test for helicobacter pylori infection: stability of samples over time. Scand J Gastroenterol 1999;34:942-943.
36. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. HEPATOLOGY 1987;7:660-664.